CN109549925B - 用于治疗细菌感染的定制脂质体 - Google Patents

用于治疗细菌感染的定制脂质体 Download PDF

Info

Publication number
CN109549925B
CN109549925B CN201811433069.8A CN201811433069A CN109549925B CN 109549925 B CN109549925 B CN 109549925B CN 201811433069 A CN201811433069 A CN 201811433069A CN 109549925 B CN109549925 B CN 109549925B
Authority
CN
China
Prior art keywords
liposomes
empty liposomes
empty
mixture
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201811433069.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN109549925A (zh
Inventor
E.巴比楚克
A.德拉伊格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Bern
Original Assignee
Universitaet Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Bern filed Critical Universitaet Bern
Publication of CN109549925A publication Critical patent/CN109549925A/zh
Application granted granted Critical
Publication of CN109549925B publication Critical patent/CN109549925B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
CN201811433069.8A 2012-06-14 2013-06-13 用于治疗细菌感染的定制脂质体 Active CN109549925B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP12171924.9 2012-06-14
EP12171924 2012-06-14
EP13153039 2013-01-29
EP13153039.6 2013-01-29
PCT/EP2013/062207 WO2013186286A1 (en) 2012-06-14 2013-06-13 Tailored liposomes for the treatment of bacterial infections
CN201380031384.7A CN104602672B (zh) 2012-06-14 2013-06-13 用于治疗细菌感染的定制脂质体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380031384.7A Division CN104602672B (zh) 2012-06-14 2013-06-13 用于治疗细菌感染的定制脂质体

Publications (2)

Publication Number Publication Date
CN109549925A CN109549925A (zh) 2019-04-02
CN109549925B true CN109549925B (zh) 2022-06-17

Family

ID=48703423

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811433069.8A Active CN109549925B (zh) 2012-06-14 2013-06-13 用于治疗细菌感染的定制脂质体
CN201380031384.7A Active CN104602672B (zh) 2012-06-14 2013-06-13 用于治疗细菌感染的定制脂质体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380031384.7A Active CN104602672B (zh) 2012-06-14 2013-06-13 用于治疗细菌感染的定制脂质体

Country Status (19)

Country Link
US (4) US10744089B2 (enExample)
EP (2) EP3782606A1 (enExample)
JP (2) JP6382801B2 (enExample)
CN (2) CN109549925B (enExample)
AU (2) AU2013276565B2 (enExample)
BR (1) BR112014031278B1 (enExample)
CA (1) CA2875470C (enExample)
CY (1) CY1123337T1 (enExample)
DK (1) DK2861214T3 (enExample)
ES (1) ES2821502T3 (enExample)
HR (1) HRP20201761T1 (enExample)
HU (1) HUE051761T2 (enExample)
LT (1) LT2861214T (enExample)
PL (1) PL2861214T3 (enExample)
RS (1) RS60951B1 (enExample)
RU (1) RU2672106C2 (enExample)
SI (1) SI2861214T1 (enExample)
SM (1) SMT202000584T1 (enExample)
WO (1) WO2013186286A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2875470C (en) * 2012-06-14 2021-01-12 Universitaet Bern Tailored liposomes for the treatment of bacterial infections
WO2015084677A1 (en) 2013-12-02 2015-06-11 Arytha Biosciences, Llc Toxoid preparation and uses thereof
US10739353B2 (en) * 2014-12-31 2020-08-11 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
WO2017115358A1 (en) 2015-12-28 2017-07-06 Mb Biotech Ltd. Liposomes for treatment of an autoimmune disease
WO2017177073A1 (en) * 2016-04-07 2017-10-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use
PL3471732T3 (pl) 2016-06-16 2020-10-19 Combioxin Sa Liposomy do leczenia infekcji wirusowych
WO2018158375A1 (en) 2017-03-02 2018-09-07 Combioxin Sa Liposomes for inhibiting biofilm formation
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
LT3781172T (lt) * 2018-04-17 2023-11-10 Combioxin Sa Pneumonijos gydymas
SMT202400412T1 (it) 2018-04-20 2024-11-15 Combioxin Sa Trattamento dell'ipotensione con sepsi o shock settico
CN111214439B (zh) * 2018-11-23 2023-02-10 复旦大学 一种具有细菌成孔毒素吸附性能的纳米药物系统及其用途
JP2023536833A (ja) * 2020-07-31 2023-08-30 サインパス ファルマ，インク． サイトカイン放出及びサイトカインストームの抑制
CN115054577B (zh) * 2022-05-17 2024-06-21 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 纳米解毒剂及其在中和mrsa穿孔毒素的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1717221A (zh) * 2002-11-26 2006-01-04 吉里德科学公司 借助梯度的脂质体中药物装填的方法
CN1939340A (zh) * 2005-09-29 2007-04-04 中国人民解放军军事医学科学院毒物药物研究所 脂质体制剂
CN1994279A (zh) * 2006-12-31 2007-07-11 西安力邦医药科技有限责任公司 注射用盐酸伊立替康脂质体的制备方法
CN101623262A (zh) * 2009-08-24 2010-01-13 海南美大制药有限公司 一种五水头孢唑啉钠前体脂质体制剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004019A1 (en) * 1989-09-12 1991-04-04 The Regents Of The University Of California Therapeutic peptides and proteins
NL9000207A (enExample) * 1990-01-29 1991-08-16 Duphar Int Res
WO1993004672A1 (en) 1991-09-11 1993-03-18 Pitman-Moore, Inc. Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US8110217B2 (en) * 2001-08-13 2012-02-07 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
EP1443900B1 (en) * 2001-11-13 2012-05-23 Celator Pharmaceuticals, Inc. Lipid carrier compositions with enhanced blood stability
CA2368656A1 (en) * 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
EP1531828A4 (en) * 2002-05-23 2005-11-02 Activbiotics Inc METHODS OF TREATING BACTERIAL INFECTIONS AND ASSOCIATED DISEASES
EP1610763A2 (en) * 2003-03-31 2006-01-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Stable liposomes or micelles comprising a sphingolipid and a peg-lipopolymer
AU2005304914B2 (en) * 2004-11-05 2012-02-16 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
WO2008039989A2 (en) * 2006-09-28 2008-04-03 Transave, Inc. Formulations of dnase and methods of use thereof
EP2088865B1 (en) * 2006-11-06 2015-10-21 Jina Pharmaceuticals Inc. Guggulphospholipid methods and compositions
CN107261110A (zh) * 2010-06-19 2017-10-20 健康科学西部大学 Peg化脂质体包封的糖肽抗生素的新制剂
SG187770A1 (en) * 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
CN102327220B (zh) 2011-07-14 2012-09-26 海南灵康制药有限公司 一种氯雷他定脂质体固体制剂
CA2875470C (en) * 2012-06-14 2021-01-12 Universitaet Bern Tailored liposomes for the treatment of bacterial infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1717221A (zh) * 2002-11-26 2006-01-04 吉里德科学公司 借助梯度的脂质体中药物装填的方法
CN1939340A (zh) * 2005-09-29 2007-04-04 中国人民解放军军事医学科学院毒物药物研究所 脂质体制剂
CN1994279A (zh) * 2006-12-31 2007-07-11 西安力邦医药科技有限责任公司 注射用盐酸伊立替康脂质体的制备方法
CN101623262A (zh) * 2009-08-24 2010-01-13 海南美大制药有限公司 一种五水头孢唑啉钠前体脂质体制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Optimization and Characterization of a Sphingomyelin/Cholesterol Liposome Formulation of Vinorelbine with Promising Antitumor Activity;SEAN C. SEMPLE et al;《Journal of Pharmaceutial Sciences》;20050531;第94卷(第5期);第1024-1038页 *

Also Published As

Publication number Publication date
EP2861214B1 (en) 2020-08-05
LT2861214T (lt) 2020-12-28
CN109549925A (zh) 2019-04-02
JP2018184470A (ja) 2018-11-22
HRP20201761T1 (hr) 2020-12-25
SMT202000584T1 (it) 2020-11-10
RU2014148284A (ru) 2016-08-10
AU2013276565B2 (en) 2018-12-20
SI2861214T1 (sl) 2021-01-29
US20200345639A1 (en) 2020-11-05
CY1123337T1 (el) 2021-12-31
US10744089B2 (en) 2020-08-18
CA2875470A1 (en) 2013-12-19
US20230031648A1 (en) 2023-02-02
PL2861214T3 (pl) 2021-02-08
BR112014031278B1 (pt) 2020-12-01
JP6656321B2 (ja) 2020-03-04
JP6382801B2 (ja) 2018-08-29
US20220087934A1 (en) 2022-03-24
JP2015519383A (ja) 2015-07-09
AU2019201776A1 (en) 2019-04-04
HUE051761T2 (hu) 2021-03-29
CA2875470C (en) 2021-01-12
CN104602672A (zh) 2015-05-06
AU2013276565A1 (en) 2014-12-18
US20150157570A1 (en) 2015-06-11
RU2018138012A (ru) 2019-03-21
EP2861214A1 (en) 2015-04-22
HK1210018A1 (en) 2016-04-15
ES2821502T3 (es) 2021-04-26
DK2861214T3 (da) 2020-10-12
WO2013186286A1 (en) 2013-12-19
RS60951B1 (sr) 2020-11-30
EP3782606A1 (en) 2021-02-24
BR112014031278A2 (pt) 2017-06-27
RU2672106C2 (ru) 2018-11-12
AU2019201776B2 (en) 2020-11-12
CN104602672B (zh) 2018-12-25

Similar Documents

Publication Publication Date Title
CN109549925B (zh) 用于治疗细菌感染的定制脂质体
JP5918922B2 (ja) 脂質を用いた薬物製剤の高速送達とその処置方法
CN1747738B (zh) 缓释抗感染剂
CN107072944B (zh) 具有抗非结核分枝杆菌活性的脂质体环丙沙星制剂
KR100438657B1 (ko) 저치밀성리포솜항균조성물
Diab et al. Insights in nanoparticle-bacterium interactions: new frontiers to bypass bacterial resistance to antibiotics
CN101511430A (zh) 抗生素组合物
US20150273025A1 (en) Apyrase treatments
RU2780026C2 (ru) Специально разработанные липосомы для лечения бактериальных инфекций
HK40046902A (en) Tailored liposomes for the treatment of bacterial infections
HK1210018B (zh) 用於治疗细菌感染的定制脂质体
ES2959435T3 (es) Tratamiento de la neumonía
US20210007985A1 (en) Liposomal anti-infective formulations to inhibit non-tuberculous mycobacteria (ntm) microaggregate formation and establishment of ntm biofilm
Alhariri Evaluation of liposomal bismuth-ethanedithiol-tobramycin for treatment of cystic fibrosis pulmonary pseudomonas aeruginosa infection
GB2554742A (en) Treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant